Literature DB >> 8593604

A spacer region between the single chain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity.

D Moritz1, B Groner.   

Abstract

The elimination of tumor cells by cytotoxic T lymphocytes (CTLs) could become the basis of a biological cancer therapy. The recognition specificity of cytotoxic T lymphocytes (CTLs) can be genetically modified by stable introduction of chimeric T cell receptor genes and thus be directed towards tumor cells. We designed a recombinant T cell receptor (TCR) component consisting of a single chain Fv derivative of a monoclonal antibody (scFv) serving as the extracellular antigen-binding domain and the zeta-chain of the TCR/CD3 complex serving as a signal transducing domain. Three chimeric receptor constructs differing in their molecular structure were derived and their functions in transduced T cells compared. A construct in which the scFv domain, specific for the ErbB-2 receptor, was fused directly to the zeta-chain, and two constructs containing different hinge regions between the functional domains, were made. The hinge regions serve as spacers which increase the distance of the scFv moiety from the plasma membrane. Only the two scFv-zeta chimeras containing a hinge region showed ErbB-2 binding activity, when expressed in T cells. The scFv-zeta construct which lacks a spacer segment did not. Consistently, only the spacer-containing chimeras transduced T cell receptor signals following ErbB-2 mediated crosslinking. An increase in intracellular Ca2+ concentrations and cytokine secretion was observed. ErbB-2 expressing tumor cells were efficiently lysed by CTLs which expressed the spacer-containing scFv-zeta chimeras. Our results will help to optimize the design of recombinant T cell receptor components useful in the grafting of a specificity of recognition on to cytotoxic T cells and possibly the gene therapy of cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8593604

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  24 in total

Review 1.  The T-body approach: potential for cancer immunotherapy.

Authors:  Z Eshhar; N Bach; C J Fitzer-Attas; G Gross; J Lustgarten; T Waks; D G Schindler
Journal:  Springer Semin Immunopathol       Date:  1996

2.  Fine-tuning the CAR spacer improves T-cell potency.

Authors:  Norihiro Watanabe; Pradip Bajgain; Sujita Sukumaran; Salma Ansari; Helen E Heslop; Cliona M Rooney; Malcolm K Brenner; Ann M Leen; Juan F Vera
Journal:  Oncoimmunology       Date:  2016-11-08       Impact factor: 8.110

Review 3.  Specific immunotherapy of cancer in elderly patients.

Authors:  S Matzku; M Zöller
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

4.  Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors.

Authors:  C O Yun; K F Nolan; E J Beecham; R A Reisfeld; R P Junghans
Journal:  Neoplasia       Date:  2000 Sep-Oct       Impact factor: 5.715

Review 5.  Ex vivo gene transfer for improved adoptive immunotherapy of cancer.

Authors:  Minhtran C Ngo; Cliona M Rooney; Jeffrey M Howard; Helen E Heslop
Journal:  Hum Mol Genet       Date:  2011-03-17       Impact factor: 6.150

Review 6.  Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.

Authors:  William R Strohl; Michael Naso
Journal:  Antibodies (Basel)       Date:  2019-07-03

Review 7.  Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.

Authors:  Marc Cartellieri; Michael Bachmann; Anja Feldmann; Claudia Bippes; Slava Stamova; Rebekka Wehner; Achim Temme; Marc Schmitz
Journal:  J Biomed Biotechnol       Date:  2010-05-05

8.  Carving the CAR.

Authors:  S R Riddell; U Protzer
Journal:  Gene Ther       Date:  2010-07-29       Impact factor: 5.250

Review 9.  Next-generation CAR T cells to overcome current drawbacks.

Authors:  Stefan Lundh; Sayantan Maji; J Joseph Melenhorst
Journal:  Int J Hematol       Date:  2020-06-27       Impact factor: 2.490

Review 10.  CAR T-cell therapy in mature lymphoid malignancies: clinical opportunities and challenges.

Authors:  Mayur Narkhede; Amitkumar Mehta; Stephen M Ansell; Gaurav Goyal
Journal:  Ann Transl Med       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.